Pancreatic cancer
It is a two arm phase III study of double vs single therapy in pancreatic cancer for those who have failed chemotherapy(first line treatment)
Who can joinAdults
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Last updated on the registry 7 Apr 2025. Please confirm with the hospital that this trial is still taking patients.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial HospitalIndiaDirections ↗
Registry summary (technical)
A randomized, open-label, double arm, phase III study of doublet vs monotherapy in advanced pancreatic cancer who have failed first-line therapy. - Panc-SELECT
Sponsor: Tata Memorial Hospital
CTRI/2022/02/040235 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 7 Apr 2025 · read by us 5 Nov 2026